First Patient Treated with Phase 1 Trial Combo of Reolysin, Opdivo, and Kyprolis
A Phase 1 trial of the combination of Reolysin (pelareorep), Kyprolis (carfilzomib), and Opdivo (nivolumab) in relapsed multiple myeloma treated the first…
Myeloma
Study Tracing Myeloma Progression from Precursor Conditions Seeks Participants
A study is recruiting participants to examine the molecular changes that occur when precursor conditions develop into full-blown multiple myeloma, information that can then be…
Janssen Seeks Darzalex Approval for Certain Newly Diagnosed Multiple Myeloma Patients in Japan
Janssen Pharmaceutical has submitted an application to Japanese authorities requesting that Darzalex (daratumumab) be approved, in combination with standard therapy, to treat newly diagnosed multiple myeloma patients…
Split Dosing Regimen of Darzalex Approved in Europe for Multiple Myeloma Patients
The European Commission has approved a new dosing regimen of the treatment Darzalex (daratumumab), allowing doctors to split the first infusion over two consecutive…
Aplidin Approved in Australia for Relapsed or Refractory Multiple Myeloma
Treatment with Aplidin (plitidepsin) in combination with dexamethasone was approved in Australia for multiple myeloma patients who have failed or are resistant to…
Triple Combo Therapy May Slow Smoldering Multiple Myeloma Progression into Overt Myeloma, Phase 2 Trial Shows
Early treatment with a triple combination therapy containing Empliciti (elotuzumab), Revlimid (lenalidomide), and dexamethasone in patients with smoldering multiple myeloma — a precursor of…
Nonprofit Launches Trial to Get Therapies to Multiple Myeloma Patients More Efficiently
The Multiple Myeloma Research Foundation (MMRF) is launching a platform clinical trial aimed at investigating treatments for high-risk multiple myeloma patients. Building on the…
Phase 2 Myeloma Trial for Investigational CAR T-cell Therapy bb2121 Completes Enrollment
An international Phase 2 trial testing the investigational CAR T-cell therapy bb2121 for the treatment of relapsed or refractory multiple myeloma patients has completed patient recruitment, …
AMG 420 Immunotherapy Shows Promise in Relapsed or Refractory Multiple Myeloma
Results from the first in-human clinical trial assessing Amgen’s immunotherapy AMG 420 showed promising results in multiple myeloma patients who had received at least…
Researchers Identify 3 Genetic Alterations Associated with Higher Risk of Myeloma in African-Americans
Researchers have identified three genetic alterations associated with the known twofold to threefold risk of multiple myeloma among African-Americans. The study, “Differences…
